Daiichi Sankyo has been granted a patent for methods to treat autoimmune diseases using monoclonal antibodies targeting domain 3 of human LAG-3. The antibodies exhibit specific binding properties and in vitro ADCC activity, while allowing LAG-3 to interact with major histocompatibility complex class II molecules. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibody for treating autoimmune diseases
The granted patent US12071478B2 outlines a method for binding an antibody or its binding fragment to human LAG-3, a protein expressed on activated human T cells. This binding occurs without inhibiting the interaction between LAG-3 and human major histocompatibility complex class II molecules. The method specifically involves contacting activated human T cells with antibodies that target domain 3 of human LAG-3. The patent details various specific amino acid sequences for the heavy and light chains of the antibodies, including multiple combinations of complementarity-determining regions (CDRs) that are critical for binding efficacy.
Additionally, the patent describes modifications to the antibodies, such as deletions at the carboxyl terminus of the heavy chains and the use of low fucose forms of the antibodies. The claims also highlight the potential therapeutic applications of these antibodies, including their ability to reduce the number of LAG-3 positive cells in vivo and suppress conditions like experimental autoimmune encephalomyelitis. Furthermore, the patent specifies that the antibodies may possess properties such as antibody-dependent cellular cytotoxicity (ADCC) and the ability to maintain LAG-3's function in T cell suppression. The antibodies can be chimeric or humanized, with a focus on enhancing their therapeutic potential.
To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
